Sök i LIBRIS databas

  Utökad sökning


Sökning: onr:"swepub:oai:gup.ub.gu.se/310855" > Amyotrophic lateral...

Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2.

Giovannelli, Ilaria (författare)
Bayatti, Nadhim (författare)
Brown, Abigail (författare)
visa fler...
Wang, Dennis (författare)
Mickunas, Marius (författare)
Camu, William (författare)
Veyrune, Jean-Luc (författare)
Payan, Christine (författare)
Garlanda, Cecilia (författare)
Locati, Massimo (författare)
Juntas-Morales, Raul (författare)
Pageot, Nicolas (författare)
Malaspina, Andrea (författare)
Andreasson, Ulf, 1968 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Suehs, Carey (författare)
Saker, Safa (författare)
Masseguin, Christophe (författare)
de Vos, John (författare)
Zetterberg, Henrik, 1973 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Al-Chalabi, Ammar (författare)
Leigh, P Nigel (författare)
Tree, Timothy (författare)
Bensimon, Gilbert (författare)
Heath, Paul R (författare)
Shaw, Pamela J (författare)
Kirby, Janine (författare)
visa färre...
visa fler...
visa färre...
Ingår i: Brain communications. - 2632-1297. ; 3:3
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
  • Amyotrophic lateral sclerosis is a fatal neurodegenerative disease causing upper and lower motor neuron loss and currently no effective disease-modifying treatment is available. A pathological feature of this disease is neuroinflammation, a mechanism which involves both CNS-resident and peripheral immune system cells. Regulatory T-cells are immune-suppressive agents known to be dramatically and progressively decreased in patients with amyotrophic lateral sclerosis. Low-dose interleukin-2 promotes regulatory T-cell expansion and was proposed as an immune-modulatory strategy for this disease. A randomized placebo-controlled pilot phase-II clinical trial called Immuno-Modulation in Amyotrophic Lateral Sclerosis was carried out to test safety and activity of low-dose interleukin-2 in 36 amyotrophic lateral sclerosis patients (NCT02059759). Participants were randomized to 1MIU, 2MIU-low-dose interleukin-2 or placebo and underwent one injection daily for 5 days every 28 days for three cycles. In this report, we describe the results of microarray gene expression profiling of trial participants' leukocyte population. We identified a dose-dependent increase in regulatory T-cell markers at the end of the treatment period. Longitudinal analysis revealed an alteration and inhibition of inflammatory pathways occurring promptly at the end of the first treatment cycle. These responses are less pronounced following the end of the third treatment cycle, although an activation of immune-regulatory pathways, involving regulatory T-cells and T helper 2 cells, was evident only after the last cycle. This indicates a cumulative effect of repeated low-dose interleukin-2 administration on regulatory T-cells. Our analysis suggested the existence of inter-individual variation amongst trial participants and we therefore classified patients into low, moderate and high-regulatory T-cell-responders. NanoString profiling revealed substantial baseline differences between participant immunological transcript expression profiles with the least responsive patients showing a more inflammatory-prone phenotype at the beginning of the trial. Finally, we identified two genes in which pre-treatment expression levels correlated with the magnitude of drug responsiveness. Therefore, we proposed a two-biomarker based regression model able to predict patient regulatory T-cell-response to low-dose interleukin-2. These findings and the application of this methodology could be particularly relevant for future precision medicine approaches to treat amyotrophic lateral sclerosis.


MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine (hsv//eng)


amyotrophic lateral sclerosis
clinical trial
low-dose interleukin 2
regulatory T cells

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy